Pages that link to "Q40628298"

The following pages link to Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children (Q40628298):

Displaying 42 items.

• Acellular vaccines for preventing whooping cough in children (Q24193554) (← links)
• Acellular vaccines for preventing whooping cough in children (Q24201103) (← links)
• Acellular vaccines for preventing whooping cough in children (Q24234899) (← links)
• Acellular vaccines for preventing whooping cough in children (Q24243261) (← links)
• Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies (Q24522458) (← links)
• Immune responses to pertussis vaccines and disease (Q26824237) (← links)
• Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation (Q30540817) (← links)
• Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data (Q31114573) (← links)
• Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA. (Q33156368) (← links)
• A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data (Q33379317) (← links)
• Acellular pertussis vaccines (Q33889544) (← links)
• Active immunization in the United States: developments over the past decade (Q33975799) (← links)
• Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection (Q33999189) (← links)
• Acellular pertussis vaccine safety and efficacy in children, adolescents and adults (Q34558806) (← links)
• Which strategy for pertussis vaccination today? (Q34626954) (← links)
• Pertussis re-emergence in the post-vaccination era (Q34636630) (← links)
• Seroprevalence of diphtheria toxoid IgG antibodies in children, adolescents and adults in Poland. (Q35046873) (← links)
• Vaccine interchangeability (Q35092870) (← links)
• Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines (Q35197423) (← links)
• Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. (Q36365668) (← links)
• Prevention of pertussis across the age spectrum through the use of the combination vaccines PENTACEL and ADACEL. (Q36541965) (← links)
• Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide (Q37034318) (← links)
• Pediatric combined formulation DTaP-IPV/Hib vaccine (Q37524018) (← links)
• Managing a child with possible allergy to vaccine (Q38153078) (← links)
• Pertussis vaccine controversies and acellular pertussis vaccine (Q39219907) (← links)
• Extensive swelling of the limb and systemic symptoms after a fourth dose of acellular pertussis containing vaccines in England in children aged 3-6years (Q40395922) (← links)
• Adverse events following booster doses of diphtheria-tetanus-inactivated poliovirus and acellular pertussis vaccines for 4-year-old children in The Netherlands. (Q40446989) (← links)
• An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vacc (Q40467229) (← links)
• Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers (Q40484747) (← links)
• Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. (Q40597029) (← links)
• Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children (Q44501609) (← links)
• The distribution over time of costs and social net benefits for pertussis immunization programs (Q44751392) (← links)
• A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4–6 years (Q57588929) (← links)
• Prevention of pertussis: Recommendations derived from the second Global Pertussis Initiative roundtable meeting (Q57589546) (← links)
• Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine (Q57769191) (← links)
• Maternal immunization with tetanus–diphtheria–pertussis vaccine: effect on maternal and neonatal serum antibody levels (Q64449061) (← links)
• Lack of consistent relationship between quantity of aluminum in diphtheria-tetanus-acellular pertussis vaccines and rates of extensive swelling reactions (Q74622680) (← links)
• Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers (Q81038737) (← links)
• Surveillance of vaccine safety: comparison of parental reports with routine surveillance and a clinical trial (Q83798645) (← links)
• Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4-6 years old (Q83880258) (← links)
• Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years (Q83945182) (← links)
• Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007-2017 (Q92471796) (← links)